![Paul Streck](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Streck
Technik-/Wissenschafts-/F&E-Leiter bei
PEPGEN INC.
Vermögen: 17 031 $ am 31.05.2026
Profil
Paul D.
Streck is Executive VP, Head-Research & Development at PepGen Inc. since 2024.
Former roles include Director-Marketing at Amgen USA, Inc. (2006–2007), Chief Medical Officer at Insmed, Inc. (2017–2019), Chief Medical Officer & SVP-Clinical Development at Arena Pharmaceuticals, Inc. (2020–2022), Group Vice President at Shire Plc (2013–2015), Group Vice President at GSK Plc, Chief Medical Officer at Lundbeck Seattle BioPharmaceuticals, Inc., and Chief Medical Officer at Albireo Pharma, Inc. Education includes undergraduate studies at Rutgers State University of New Jersey, graduate studies at Sidney Kimmel Medical College, and an MBA from The Fuqua School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PEPGEN INC. 0,02 % | 31.03.2026 | 11.354 ( 0,02 % ) | 17 031 $ | 31.05.2026 |
Aktive Positionen von Paul Streck
| Unternehmen | Position | Beginn |
|---|---|---|
| PEPGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.08.2024 |
Ehemalige bekannte Positionen von Paul Streck
| Unternehmen | Position | Ende |
|---|---|---|
| ARENA PHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | 11.03.2022 |
| INSMED INCORPORATED | Technik-/Wissenschafts-/F&E-Leiter | 18.01.2019 |
| SHIRE | Corporate Officer/Principal | 01.11.2015 |
Amgen USA, Inc.
 Amgen USA, Inc. BiotechnologyHealth Technology Manufactures biological products | Vertrieb & Marketing | 01.10.2007 |
| ALBIREO PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Paul Streck
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
25
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Insmed, Inc.
 Insmed, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
Sidney Kimmel Medical College
 Sidney Kimmel Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Fuqua School of Business
 The Fuqua School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Amgen USA, Inc.
Amgen USA, Inc. BiotechnologyHealth Technology Manufactures biological products | Health Technology |
PepGen Inc.
 PepGen Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company which develops oligonucleotide therapeutics for treatment of severe neuromuscular and neurologic diseases | Health Technology |
